Short Interest in Genus plc (OTCMKTS:GENSF) Increases By 32.9%

Genus plc (OTCMKTS:GENSFGet Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 49,507 shares, a growth of 32.9% from the January 29th total of 37,249 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Genus in a report on Thursday, November 20th. One analyst has rated the stock with a Buy rating, According to MarketBeat, Genus currently has a consensus rating of “Buy”.

Check Out Our Latest Analysis on Genus

Genus Stock Performance

OTCMKTS GENSF opened at $37.25 on Monday. Genus has a 1 year low of $35.00 and a 1 year high of $37.25. The company has a fifty day moving average of $36.19 and a two-hundred day moving average of $35.37.

Genus Company Profile

(Get Free Report)

Genus plc, trading on the OTCMKTS under the symbol GENSF, is a global leader in innovative animal genetics and breeding solutions. The company operates through two primary business segments: ABS and PIC. ABS focuses on bovine genetics, offering dairy and beef cattle semen, advanced reproductive technologies and digital herd management tools. PIC specializes in porcine genetics, providing breeding stock, genetic evaluation services and production support aimed at optimizing growth performance, health and sustainability across the global swine industry.

With origins dating back to its establishment in 1933 as the British Dairy Cattle Breeders’ Society, Genus has expanded through strategic acquisitions and organic growth to build a leading position in animal biotechnology.

Recommended Stories

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.